O'Connell and Doherty emphasized that the decision to advance EBD candidates will be data-driven in early 2026.
Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year Product ...
Selected lead candidates AL137 for the company’s Alector Brain Carrier (ABC)-enabled anti-amyloid beta antibody in Alzheimer's disease, and AL050 ...
NEO-CYT is a randomized, multi-centre trial of neoadjuvant MDNA11 (before curative intent surgery) sponsored by the Fondazione Melanoma Onlus, ...
In a world that chases fitness and wellness amidst the hustle of daily lives, weight loss jabs have become the magic pills ...
Pfizer Inc. ( PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology November 10, 2025 8:30 AM EST ...
Learn more about whether Protagonist Therapeutics, Inc. or Viridian Therapeutics, Inc. is a better investment based on AAII's ...
CuraSen Therapeutics, Inc., a biopharmaceutical company developing drug candidates with broad applicability in neurodegenerative and neuropsychiatric diseases, today announced encouraging results from ...
Adolescents treated with doxycycline were up to one third less likely to develop schizophrenia as adults, a Finnish study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback